Pinealon (EDR)
Synthetic Tripeptide | Neuroprotection & Cognitive Enhancement
Community Research
Join others researching Pinealon — share findings, ask questions, and learn from real experiences
Developed in Russia, Pinealon demonstrates unique DNA-interaction for neuroprotection and cognitive enhancement. Benefits traumatic brain injury recovery and age-related cognitive decline with excellent safety profile.
Penetrates nuclear membranes to directly interact with DNA, modulates gene expression via histone H1.3 binding and MAPK/ERK pathway activation.
Molecular Data
ED?Glutamic Acid
Position 1
Aspartic Acid
Position 2
Arg (EDR)
Position 3
Research Indications
Clinical protocol of 5mg daily showed significant cognitive improvements in 72-patient study.
Subcutaneous administration allows systemic circulation to brain tissue for neuroprotective effects.
Caspase-3 suppression, ROS reduction, and excitotoxicity protection.
Enhanced neurotransmitter function with 1.9x serotonin increase in cell cultures.
100 ng/kg optimal dose improved spatial learning in hippocampus.
Irisin expression increases linked to telomere protection and mitochondrial enhancement.
32-patient study showed significant improvements in aging indicators over 20-30 days.
Dosing Protocols
Highest bioavailability, direct systemic delivery, established clinical protocols.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuroprotection | 5mg daily | Once daily | SubQ |
| Cognitive Enhancement | 100-300mcg | Daily or every other day | SubQ |
| Anti-aging | 5mg | 20 days, 2-3x yearly | SubQ |
Reconstitution Instructions
- Lyophilized Pinealon powder
- Bacteriostatic water for injection
- Insulin syringes (30-31 gauge)
- Alcohol swabs
- 1 Remove powder and water from refrigeration
- 2 Clean vial tops with alcohol swabs; allow to dry
- 3 Draw bacteriostatic water into syringe
- 4 Inject water slowly down vial side to avoid foam
- 5 Gently swirl until completely dissolved
- 6 Store at 2-8°C
- 7 Use within 30 days
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Minimal injection site reactions
- Mild gastrointestinal adjustment
- Occasional headache
- Fatigue
Stop Signs - Discontinue if:
- Severe headaches or mood changes
- Persistent injection site reactions
- Signs of infection at injection site
- Unusual neurological symptoms
- Allergic reactions
Contraindications
- Pregnancy
- Lactation
Quality Checklist
Good Signs
- White crystalline powder; proper freeze-drying indicated
- Clear reconstituted solution; no particles or cloudiness
- Pharmaceutical packaging with batch numbers from reputable sources
Warning Signs
- Ensure distinction between research (lab only) and pharmaceutical (human use) grade
Bad Signs
- Discolored powder (yellow or brown) indicates degradation from heat or moisture
- Cloudy solution indicates contamination
References
- Human Clinical Trial - Post-Traumatic Cerebrasthenia(2015)
72 patients aged 30-74; 0.2mg twice daily; 20-30 days. Improved memory, reduced headache severity, and enhanced emotional stability compared to controls.
- Aging Study - Polymorbidity Patients(2015)
32 patients aged 41-83; variable dosing; 30 days. Significant improvements in biological aging biomarkers with anabolic effects.
- Diabetic Rat Model - Spatial Learning(2020)
100 ng/kg optimal dose; 14 days. Enhanced NMDA receptor expression in hippocampus with neuroplasticity improvements.
- 5xFAD Alzheimer's Mouse Model(2021)
400 μg/kg IP daily; 28 days. Prevention of dendritic spine loss through MAPK/ERK pathway modulation.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.